Johnson & Johnson announced significant positive updated and new data for Rybrevant (amivantamab) with lazertinib in first-line non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) meeting.
The bispecific epidermal growth factor receptor (EGFR)/cMET inhibitor and oral EGFR tyrosine kinase inhibitor combo demonstrated benefits in the first-line...